# Medical Question & Answer

**Sample ID**: d7995a38-8362-418d-b9ad-05e68aed218f
**Dataset Index**: 4218

---

## Question

Which direct oral anticoagulant prevents varicose veins?

---

## Answer

> Let's see… What do we have here? The user is asking which, if any, direct oral anticoagulant (DOAC) can prevent varicose veins. Let's break this down step-by-step. First, I need to think about the pathophysiology of varicose veins and whether coagulation targets plausibly alter that biology. Then, I should verify what contemporary venous guidelines and high-quality reviews say about any preventive role for DOACs in chronic venous disease. Next, I will examine how DOACs are actually used in this domain: treatment of superficial vein thrombosis (SVT), peri-procedural thromboprophylaxis, and management of post-procedural thrombotic complications. Finally, I will synthesize whether any of these translate to primary prevention of varicose veins themselves, anchoring my conclusions to guideline statements and evidence summaries.

> Let me first confirm the core biology. Varicose veins stem from venous wall remodeling and valvular incompetence driven by genetic predisposition, hormonal and biomechanical influences, and chronic venous hypertension; this is a structural and hemodynamic problem, not a primary coagulation disorder. DOACs inhibit factor Xa or thrombin to prevent thrombosis; they do not repair venous valves or reverse extracellular matrix changes in the venous wall, so mechanistically they would not be expected to prevent varicose vein formation or progression.

> Next, I should review what the major venous guidelines actually recommend. Hold on, let's not jump to conclusions — I need to check the AVF/AVLS/SVS 2023–2024 guidance and related evidence syntheses for any statement suggesting DOACs prevent varicose veins in asymptomatic or symptomatic C2 disease. I will now examine those documents with attention to sections on prevention, conservative care, and thromboembolic risk around procedures.

> I will now examine the SVT context, because that is where anticoagulants are most often discussed in patients who happen to have varicose veins. The guidelines recommend anticoagulation for defined SVT scenarios — fondaparinux 2.5 mg daily for 45 days, with rivaroxaban 10 mg daily for 45 days as an alternative when injections are not feasible — because the goal is preventing SVT extension and VTE, not preventing varicose veins themselves [^1174x9Hp] [^112Ma4mC]. Wait, let me verify the anatomic caveat: when SVT is within 3 cm of the saphenofemoral junction, full-dose anticoagulation for at least 6 weeks is advised, again targeting thrombotic risk rather than venous wall disease [^1174x9Hp].

> Now, I should double-check peri-procedural thromboprophylaxis after endovenous ablation. Systematic reviews and AVF/AVLS/SVS guidance suggest pharmacological thromboprophylaxis can reduce DVT events compared with mechanical measures alone in selected or higher-risk cohorts, but the absolute risk is low and evidence heterogeneous; moreover, this strategy mitigates post-procedural VTE and EHIT risk, not the emergence or recurrence of varicose veins per se [^1125uAa8] [^113jqpJ8]. Let me verify effect sizes: pooled randomized trial arms show DVT around 0.5% with additional pharmacoprophylaxis versus about 2.3% with mechanical measures alone, acknowledging heterogeneity and bias in broader datasets [^115AmgiR].

> Next, I should review management of post-procedural thrombotic complications. For acute proximal DVT after a varicose vein procedure and for ablation-related thrombus extension (ARTE) or higher-grade EHIT, guidelines prefer DOACs over VKAs to treat the thrombotic complication; again, this is reactive management of clots, not prevention of varicose vein disease biology [^116f896k] [^116RTxiv]. I need to ensure consistency across documents — multiple guideline sections converge on DOACs as first-line anticoagulants in these scenarios based on ease of use and comparable or favorable safety-effectiveness profiles versus VKAs [^112Dx2yP].

> But wait, what about primary prevention of varicose veins or their progression in people without symptoms? Let me reconsider the explicit prevention statements. The AVF/AVLS/SVS guideline advises against prophylactic intervention to prevent venous disease progression in asymptomatic C2 disease, and there is no role for anticoagulation as a preventive measure; conservative approaches like compression are used for symptom control rather than disease prevention in this context [^114KvTzw] [^117BRpjP]. I should confirm there is no hidden pharmacologic prevention signal — none is described in ESVS chronic venous disease guidance either, which focuses on treating reflux and symptomatic tributaries rather than anticoagulant-based prevention of varicosities [^notfound].

> I need to ensure the biological rationale aligns with the guidance. DOACs act downstream in the coagulation cascade and do not modulate venous valve competence, extracellular matrix remodeling, or ambulatory venous hypertension — the processes that drive varicose vein formation and progression — so there is no mechanistic basis to expect primary or secondary prevention of varicose veins from anticoagulation alone. Hold on, I should verify whether any hypothesis papers suggest otherwise; conceptual discussions about the genetics and vessel remodeling of varicose veins reinforce a structural paradigm, not a coagulation-mediated one.

> Hmm, wait a minute — could there be confusion with "varices" elsewhere in the body where pharmacologic prevention is standard? I should double-check that I am not conflating lower-extremity varicose veins with portal hypertensive gastroesophageal varices, where nonselective beta-blockers and band ligation are used to prevent bleeding; those recommendations are specific to portal hypertension and do not apply to leg varicosities, and DOACs are not used to prevent variceal formation there either [^1112i6th] [^1147qzxV]. That confirms we shouldn't generalize across distinct venous pathologies simply because they share the term "varices".

> Synthesis and conclusion: I should confirm that every mention of DOACs in the varicose vein literature pertains to thrombotic indications — treating SVT, reducing peri-procedural VTE risk in selected patients, or treating ARTE/EHIT or post-procedural DVT — and none supports preventing the development, progression, or recurrence of varicose veins themselves; taken together, the guidelines and evidence do not endorse DOACs for varicose vein prevention [^112Ma4mC] [^1174x9Hp]. Therefore, no direct oral anticoagulant prevents varicose veins; their role is antithrombotic, not disease-modifying for venous wall or valve pathology, and prevention strategies should instead focus on addressing reflux with procedural therapy when indicated and on conservative measures for symptom control where appropriate [^113jqpJ8] [^117BRpjP].

---

None of the direct oral anticoagulants (DOACs) **prevent varicose veins**. Varicose veins result from venous valve incompetence and structural vein wall changes — not thrombosis — so anticoagulation does not address the underlying pathology. DOACs are used to treat or prevent thrombotic complications (DVT, PE, SVT) in patients with varicose veins [^112xokAm] [^1111TYHe] [^1174x9Hp], but they do not prevent varicose vein development or progression [^114KvTzw]. Prevention and management of varicose veins rely on **compression therapy, lifestyle changes, and procedural interventions**, not anticoagulation [^117BRpjP].

---

## Pathophysiology of varicose veins

Varicose veins **result from chronic venous insufficiency (CVI)**, characterized by:

- **Venous valve incompetence**: Reflux and venous hypertension.

- **Vein wall remodeling**: Dilation and tortuosity.

- **Risk factors**: Age, female sex, pregnancy, obesity, prolonged standing, and family history [^115HBdjL].

The primary pathology is mechanical and structural — **not thrombotic** — so anticoagulation does not address the root cause.

---

## Role of anticoagulation in varicose veins

Anticoagulation is indicated in varicose vein patients **only when thrombotic complications occur**, such as:

- **Deep vein thrombosis (DVT)**: Acute or chronic [^112xokAm].

- **Pulmonary embolism (PE)**: Associated with DVT [^1111TYHe].

- **Superficial vein thrombosis (SVT)**: Especially when extensive or near the saphenofemoral junction [^1174x9Hp].

DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) are effective for treating and preventing these complications [^117CffWw]; however, they **do not prevent varicose veins**.

---

## Clinical evidence and guidelines

Current clinical guidelines and evidence clearly state that anticoagulation, including DOACs, **does not prevent varicose veins**:

- **AVF/AVLS/SVS 2024 guidelines**: Recommend DOACs for thrombotic complications (DVT, PE, SVT) in varicose vein patients, but not for preventing varicose veins [^112Ma4mC].

- **ESVS 2022 guidelines**: Emphasize anticoagulation for thrombotic events, not for preventing varicose veins.

- **SURPRISE trial**: Rivaroxaban was non-inferior to fondaparinux for preventing thromboembolic complications in SVT, but did not prevent varicose veins [^1174x9Hp].

---

## Alternative preventive strategies

Preventing varicose veins relies on mechanical support, lifestyle changes, and procedures tailored to disease severity. **Compression therapy** is the primary conservative approach to reduce symptoms and slow progression [^117BRpjP]. Lifestyle modifications — such as weight control, regular exercise, and avoiding prolonged standing — help address modifiable risks [^115HBdjL]. Endovenous ablation, sclerotherapy, or surgical ligation are used for symptomatic or advanced disease.

---

## Risks and limitations of anticoagulation

Using anticoagulation solely to prevent varicose veins is **inappropriate and risky** because it exposes patients to major and minor bleeding, particularly in those at higher bleeding risk [^116AwGWf]. It offers no structural benefit because anticoagulation **does not improve valve function or vein wall integrity**, and it conflicts with evidence and guidelines, which do not support anticoagulation for primary prevention of varicose veins [^114KvTzw] [^111Ns9vn].

---

## Summary of evidence

| **Intervention** | **Effect on varicose veins** | **Clinical evidence** |
|-|-|-|
| DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) | - No prevention of varicose veins <br/> - Used for thrombotic complications | - AVF/AVLS/SVS 2024 guidelines [^112Ma4mC] [^111Ns9vn] <br/> - SURPRISE trial [^1174x9Hp] |
| Compression therapy | Reduces symptoms and slows progression | AVF/AVLS/SVS 2023 guidelines [^117BRpjP] |
| Lifestyle modifications | Reduces risk factors and progression | AVF/AVLS/SVS guidelines [^112Ma4mC] |
| Procedural interventions | Treats existing varicose veins | AVF/AVLS/SVS guidelines [^112Ma4mC] [^111MJnrG] |

---

No DOAC **prevents varicose veins** because the disease is driven by valve incompetence and vein wall changes, not thrombosis. DOACs are for thrombotic complications — not for preventing varicose veins — and prevention relies on compression, lifestyle measures, and procedures [^112xokAm] [^1111TYHe] [^117BRpjP].

---

## References

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^112Ma4mC]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). High credibility.

Regarding specific circumstances for varicose veins, particularly with respect to patients with superficial vein thrombosis, the AVF/AVLS/SVS 2024 guidelines recommend administering fondaparinux 2.5 mg SC daily for 45 days. This is advised for patients with superficial vein thrombosis of the main saphenous trunks and tributaries above the knee, situated more than 3 cm from the saphenofemoral junction and exceeding 5 cm in length, irrespective of association with varicose veins. Consider administering rivaroxaban 10 mg/day for 45 days as an alternative in patients unwilling or unable to administer subcutaneous injections.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^111Ns9vn]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). High credibility.

Regarding follow-up and surveillance for varicose veins, more specifically with respect to the management of postprocedural DVT, the AVF/AVLS/SVS 2024 guidelines recommend considering the administration of anticoagulation in patients with isolated distal DVT following a varicose vein procedure, especially if they present with symptoms or risk factors for extension.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^112Dx2yP]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). High credibility.

Regarding follow-up and surveillance for varicose veins, particularly concerning the management of postprocedural deep vein thrombosis (DVT), the AVF/AVLS/SVS 2024 guidelines recommend administering anticoagulation with direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) in patients with acute proximal DVT following a varicose vein procedure.

---

### The importance of antiphospholipid syndrome testing in venous thromboembolism after varicose vein surgery [^1112spbm]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2020). Low credibility.

Anticoagulation treatment following a venous thromboembolism event is usually managed on a case-by-case basis. The risk of thrombosis must be weighed against the risk of bleeding. Identifying patients who could benefit from anticoagulation therapy requires the thromboembolism event to be assessed concerning its presentation and the severity of the triggering factors. A case report is employed to explain the important aspects of practical approaches to venous thromboembolism events after vein surgery. The Trial on Rivaroxaban in Antiphospholipid Syndrome (TRAPS) study has prompted new considerations for anticoagulation management. Patients with antiphospholipid syndrome need to be identified early to lower the risk of thromboembolism also during anticoagulation treatment.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^114rm71m]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). High credibility.

The 2024 guidelines from AVF/AVLS/SVS recommend offering sclerotherapy with liquid or foam to patients with symptomatic telangiectasias and reticular veins. This recommendation pertains specifically to the management of these conditions in the context of therapeutic procedures for varicose veins.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^116f896k]. Journal of Vascular Surgery, Venous and Lymphatic Disorders (2024). High credibility.

- **Guideline**: Grade of recommendation: 2 (weak), Quality of Evidence: C (low to very low)

	11.3.3. For patients with acute proximal DVT following a varicose vein procedure, we recommend anticoagulation with a direct oral anticoagulant over a vitamin K antagonist.

- **Guideline**: Grade of recommendation: 1 (strong), Quality of Evidence: B (moderate)

	11.3.4. For patients with symptomatic ARTE after endovenous ablation, we recommend anticoagulation with a direct oral anticoagulant over a vitamin K antagonist.

- **Guideline**: Grade of recommendation: 1 (strong), Quality of Evidence: C (low to very low)

	11.4.1. For patients with asymptomatic ARTE III and IV after endovenous ablation, anticoagulation with a direct oral anticoagulant over a vitamin K antagonist should be performed.

- **Consensus statement**:

	11.4.2. For patients who receive anticoagulation for ARTE following endovenous ablation, treatment should be continued until the thrombus retracts.

---

### U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients [^1147qzxV]. Gut (2015). High credibility.

Regarding medical management for gastroesophageal varices, specifically concerning primary prevention of variceal hemorrhage, BSG 2015 guidelines recommend initiating nonselective β-blockers or performing variceal band ligation for primary prophylaxis. Consider initiating pharmacotherapy with propranolol (40 mg BID, titrate dose to the maximum tolerated or until a heart rate of 50–55 bpm is reached, with a maximum dose of 320 mg) as the first-line primary prophylaxis. Offer variceal band ligation if nonselective β-blockers are contraindicated or not tolerated. Take into account patient choice when deciding between variceal band ligation and nonselective β-blockers.

---

### Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions [^112GAb3J]. Annals of Surgery (2023). High credibility.

The inherent risk of pharmacological thromboprophylaxis is the risk of bleeding. There was insufficient reporting of this outcome to perform a quantitative analysis, so a narrative review was performed. Qualitative studies have demonstrated reticence of patients to engage with thromboprophylaxis regimes, chiefly because of the lack of education about the risks of VTE, lack of involvement in the risk assessment process, and low acceptability of self-injection. Direct oral anticoagulants have been used for pharmacological thromboprophylaxis after surgery without increasing the major bleeding risk; however, minor bleeding events were more common. The data collected in this study support a similar hypothesis, with low rates of minor bleeding and just one instance of major bleeding across all the studies, due to NSAID and LMWH coadministration. Given the relative lack of safety data, it is imperative that primary safety endpoints, such as bleeding and VTE-related mortality, are reported by all future observational and interventional studies as per established international guidance.

In this study, all endovenous treatment modalities were considered together to enhance the amount of literature that could be analyzed. No significant difference in DVT rates for different endovenous closure modalities has been reliably demonstrated, and post hoc analysis demonstrated no correlation between type of intervention and rate of DVT. In the same way, treatment of incompetent SSV and anterior accessory saphenous vein was included in quantitative analyses. Although some have discussed a trend.

---

### Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis [^113VGa2J]. European Journal of Gastroenterology & Hepatology (2021). Low credibility.

The objective of this study was to evaluate the efficacy and safety of direct oral anticoagulants compared to warfarin for the treatment of portal vein thrombosis.

- **Methods**: This was a single-center, retrospective study. Adult patients initiated on a direct oral anticoagulant or warfarin for the treatment of a new portal vein thrombosis were included. The primary failure outcome was the absolute difference in thromboembolic events 90 days following initiation of a direct oral anticoagulant versus warfarin. The primary safety outcome was the absolute difference in bleeding events 90 days following initiation of a direct oral anticoagulant versus warfarin. Descriptive statistics, Fisher's exact test, and Student's t-tests were utilized as appropriate.

- **Results**: Thirty-three patients were included. Thirteen (39.4%) patients received direct oral anticoagulants, and 20 (60.6%) received warfarin. None of the patients receiving direct oral anticoagulants experienced a primary failure event compared to four receiving warfarin (P < 0.001). None of the patients receiving direct oral anticoagulants experienced a primary safety event versus one receiving warfarin (P < 0.001).

- **Conclusion**: Direct oral anticoagulants appear to be effective and safe in the treatment of portal vein thrombosis and in preventing thromboembolic events. Future studies with larger sample sizes are warranted to confirm the efficacy of direct oral anticoagulants in portal vein thrombosis.

---

### Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: The multicenter, multinational, randomized, open-label ARIVA trial [^116EYn7i]. Circulation (2025). Low credibility.

In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial (Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS) tested whether 100 mg of daily aspirin plus 20 mg of rivaroxaban is superior to 20 mg of rivaroxaban alone to prevent stent thrombosis within 6 months after stent placement for post-thrombotic syndrome.

- **Methods**: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score > 4 points and a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein successfully treated with venous stent placement were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included age > 75 years, contraindications to anticoagulant use, or acute venous thrombosis < 3 months. The primary efficacy outcome was the composite of no occlusion in the treated segment, assessed at serial duplex ultrasound examinations, or no reintervention needed to maintain patency within 6 months. Secondary outcomes, including Villalta score, quality of life, and safety outcomes, were also assessed. The study was registered at (NCT04128956).

- **Results**: From 2020 through 2022, 172 patients were screened, 169 were randomized, and 162 were included in the full analysis set, receiving either aspirin plus rivaroxaban.

---

### The 2023 society for vascular surgery, American venous forum, and American vein and lymphatic society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the society of interventional radiology and the society for vascular medicine [^113jqpJ8]. Journal of Vascular Surgery, Venous and Lymphatic Disorders (2024). High credibility.

This guideline is consistent with that previously suggested by the AVF/SVS. Other guidelines include those from the UK Royal Society of Medicine, which suggest preoperative assessment of all patients for both VTE and bleeding risk with pharmacological prophylaxis for 7 to 14 days in intermediate-risk patients and for 4 to 6 weeks in high-risk patients. The European Society for Vascular Surgery recommends VTE risk assessment in all patients with consideration of individualized thromboprophylaxis (Class IIa, Level B).

Although the weight of the evidence does suggest some benefit to pharmacological thromboprophylaxis, the evidence is difficult to generalize due to the limited magnitude of effect among those systematic reviews reporting a benefit of routine thromboprophylaxis (number needed to treat 25.4–172.4 for the prevention of DVT), lack of risk stratification in most studies, and significant heterogeneity in the results. In addition to the uncertain value of routine thromboprophylaxis, there is little data regarding optimal agents, dose, or duration of thromboprophylaxis if used. We therefore suggest pharmacoprophylaxis in high-risk patients, but with a low certainty of evidence.

---

### Oral factor Xa and direct thrombin inhibitors: A clinical perspective [^11642kR4]. Journal of Burn Care & Research (2012). Low credibility.

Oral anticoagulation used to be synonymous with warfarin until the recent approval of oral direct thrombin inhibitors and factor Xa inhibitors in the United States and other countries across the world. Thrombosis prevention and treatment continue to be the main objective and goal for surgical and medical patients. Regulatory agencies continue to revise their guidelines to treat these patients with appropriate medication and for optimal duration.

As the choices for oral anticoagulants increase, with many oral anticoagulant drugs currently in the pipeline awaiting completion of clinical trials, the guidelines for venous thromboembolism prevention, stroke prevention in atrial fibrillation, and treatment of acute arterial and venous thrombi will also shift from the standards to new standards set by these clinical trials for optimal dosing and duration of treatment. However, it must be reinforced that these new oral anticoagulants are distinct pharmacological compounds with specific targets and will also have distinct clinical indications for use.

---

### Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions [^1125uAa8]. Annals of Surgery (2023). High credibility.

The primary objective of this systematic review and meta-analysis was to elucidate the rate of venous thromboembolism (VTE) after endovenous interventions for varicose veins in the presence of pharmacological and mechanical thromboprophylaxis versus mechanical thromboprophylaxis alone. The VTE rate after endovenous procedures for varicose veins is higher than other day-case procedures and could be reduced with pharmacological thromboprophylaxis.

- **Methods**: The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines with a registered protocol (PROSPERO: CRD42021274963). Studies of endovenous intervention for superficial venous incompetence reporting the predefined outcomes with at least 30 patients were eligible. Data were pooled with a fixed effects model.

- **Results**: There were 221 trials included in the review (47 randomized trial arms, 105 prospective cohort studies, and 69 retrospective studies). In randomized trial arms, the rate of deep venous thrombosis with additional pharmacological thromboprophylaxis was 0.52% (95% CI, 0.23%–1.19%) (9 studies, 1095 patients, 2 events) versus 2.26% (95% CI, 1.81%–2.82%) (38 studies, 6951 patients, 69 events) with mechanical thromboprophylaxis alone. The rate of pulmonary embolism in randomized trial arms with additional pharmacological thromboprophylaxis was 0.45% (95% CI, 0.09–2.35) (5 studies, 460 participants, 1 event) versus 0.23% (95% CI, 0.1%–0.52%) (28 studies, 4834 participants, 3 events) for mechanical measures alone. The rate of EHIT grade III to IV was 0.35%.

---

### Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions [^1122BTdx]. Annals of Surgery (2023). High credibility.

The most significant limitation of this meta-analysis is the lack of direct head-to-head randomized trials comparing additional pharmacological thromboprophylaxis to mechanical measures alone. Therefore, network and standard meta-analysis were precluded, and a metaproportions approach was taken to aggregate the data from randomized trial arms and observational studies. The observational study arms introduced a significant amount of bias into the analysis, chiefly through confounding by indication. Trial arms in which pharmacological thromboprophylaxis was administered may have done so for a perceived higher risk of thrombosis in the cohort. Likewise, participants in the mechanical thromboprophylaxis alone trial arms are more likely to have been recruited to the trial because of their low perceived VTE risk. However, this bias is likely to diminish the effect size reported rather than increase it. That is, the VTE rate may be overestimated for pharmacological in addition to mechanical thromboprophylaxis. This selection bias makes the quality of evidence for the pooled rate of DVT inherently weaker and explains the downgrading of evidence from high to moderate quality in the GRADE assessment. Although there are no direct head-to-head comparisons, the data extracted from randomized trial arms limits the level of confounding by indication and provides a less biased review of the pooled VTE rate for pharmacological in addition to mechanical thromboprophylaxis versus mechanical thromboprophylaxis alone. Thus, the randomized data are the most important findings presented.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^1141dL6X]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). High credibility.

A second broader meta-analysis included 47 randomized trials, 105 prospective cohort studies, 67 retrospective cohort studies, and 2 case-control studies, encompassing a total of 476,266 patients undergoing a variety of superficial endovenous interventions, excluding open venous surgery. Notably, most studies excluded patients with a history of DVT. Although significant heterogeneity precluded analysis of all study arms, among prospective studies, additional pharmacological prophylaxis reduced the incidence of DVT to 0.73% (95% CI, 0.52%-1.02%) from 1.31% (1.15%-1.48%) for mechanical prophylaxis alone (compression stockings/bandages). No significant difference was noted between single-dose and extended pharmacoprophylaxis.

There were no significant differences in PE (0.14%, 0.07%-0.28% vs 0.16%, 0.15%-0.18%) or EHIT III to IV (0.35%, 0.09%-1.40% vs 0.88%, 0.28%-2.70%) when comparing pharmacoprophylaxis to mechanical prophylaxis alone. Major bleeding was quite rare (1 case), while minor bleeding was observed in 0% to 10% of patients. The risk of bias was estimated to be high, and the quality of evidence was moderate among randomized trials and very low among nonrandomized trials.

A systematic review included in the AVF/SVS EHIT guidelines, which included only retrospective observational studies, failed to show a lower incidence of EHIT with pharmacological thromboprophylaxis.

- **For patients undergoing endovenous ablation**: Routine risk stratification should be performed to assess the need for periprocedural thromboprophylaxis.

---

### Does aspirin prevent venous thromboembolism [^1168joFP]. Hematology. American Society of Hematology. Education Program (2020). Low credibility.

Venous thromboembolism (VTE; deep vein thrombosis and/or pulmonary embolism) is a well-established cause of morbidity and mortality in the medical and surgical patient populations. Clinical research in the prevention and treatment of VTE has been a dynamic field of study, with investigations into various treatment modalities ranging from mechanical prophylaxis to direct oral anticoagulants. Aspirin has long been an inexpensive cornerstone of arterial vascular disease therapy, but its role in the primary or secondary prophylaxis of VTE has been debated.

Risk-benefit tradeoffs between aspirin and anticoagulants have changed, in part due to advances in surgical technique and postoperative care, and in part due to the development of safe, easy-to-use oral anticoagulants. We review the proposed mechanisms in which aspirin may act on venous thrombosis, the evidence for aspirin use in the primary and secondary prophylaxis of VTE, and the risk of bleeding with aspirin as compared with anticoagulation.

---

### Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism [^1111C9de]. European Heart Journal (2014). Low credibility.

Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute and long-term prevention of venous thromboembolism (VTE). They are at least as effective and as safe as conventional therapy — such as heparins and vitamin-K inhibitors — and have practical advantages, including fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients, and the optimal management of bleeding complications is evolving.

---

### Oral anticoagulants in the management of venous thromboembolism [^111AMGWg]. Nature Reviews Cardiology (2013). Low credibility.

Despite advances in diagnosis, prevention, and management, venous thromboembolism (VTE) remains a common cause of morbidity and mortality. For decades, antithrombotic therapy for the prevention and treatment of VTE was limited to parenteral agents related to heparin and oral vitamin K antagonists (VKAs). Both classes of anticoagulants are effective but have limitations. These include considerable variability in dose-response, narrow therapeutic margins between thrombosis and bleeding risks, and the need to monitor anticoagulation intensity.

Over the past decade, the introduction of new oral anticoagulants that specifically inhibit coagulation factors IIa (thrombin) or Xa has changed practice in a variety of clinical situations, including VTE prophylaxis and treatment. This review outlines the use of novel oral anticoagulants such as apixaban, dabigatran, edoxaban, and rivaroxaban in the prevention and treatment of VTE, and discusses practical considerations for choosing the appropriate drug for each patient.

Although the introduction of novel anticoagulant drugs is promising, selecting the optimal strategy for an individual patient requires an understanding of the specific circumstances associated with thrombus formation and the pharmacological properties of each agent.

---

### Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis [^111EiCy3]. European Journal of Gastroenterology & Hepatology (2020). Low credibility.

This study is designed to investigate the efficacy and safety of direct-acting oral anticoagulants (DOACs) for the treatment of chronic portal vein thrombosis (PVT) in liver cirrhosis patients.

- **Materials and methods**: In a prospective cohort study, patients were divided into a DOACs group (oral rivaroxaban tablets or dabigatran etexilate capsules) and a control group (no anticoagulant treatment). Based on the propensity score matching method, 40 patients with cirrhosis and chronic PVT in each group were recruited for this study. CT portal venography was used to monitor the portal vein area, while color Doppler ultrasound was employed to monitor the portal vein flow rate. Biochemical testing and thromboelastography (TEG) were also used for monitoring the status of PVT.

- **Results**: After 3 months of DOACs treatment, the complete/partial recanalization rate of DOACs was 12.8% (5/39). After 6 months of treatment, this rate increased to 28.2% (11/39), with higher recanalization rates and portal vein flow velocity improvement observed compared to the control group (P < 0.05).

- **Conclusion**: DOACs are effective and safe for treating chronic PVT in patients with liver cirrhosis. TEG can predict the risk of bleeding in patients with chronic PVT.

---

### Pradaxa [^112jhUSv]. U.S. Food and Drug Administration (2023). High credibility.

For the efficacy evaluation, all patients were to undergo bilateral venography of the lower extremities 3 days after the last dose of the study drug, unless an endpoint event had occurred earlier in the study. In the primary efficacy analysis, PRADAXA Capsules, administered at 110 mg orally 1–4 hours after surgery followed by 220 mg daily, was found to be non-inferior to enoxaparin 40 mg once daily. This was assessed using a composite endpoint of confirmed venous thromboembolism (VTE), which included proximal or distal deep vein thrombosis (DVT) on venogram, confirmed symptomatic DVT, or confirmed pulmonary embolism (PE), as well as all-cause mortality during the treatment period. In the studies, 2628 patients (76.5%) in RE-NOVATE and 1572 patients (78.9%) in RE-NOVATE II had evaluable venograms at study completion.

---

### The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex scanning and treatment of superficial truncal reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology [^117BRpjP]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2023). High credibility.

Regarding nonpharmacologic interventions for varicose veins, more specifically with respect to compression therapy, the AVF/AVLS/SVS 2023 guidelines recommend considering offering compression therapy as a primary treatment for either a trial period or definitive management in patients with symptomatic varicose veins and axial reflux in the superficial truncal veins. This recommendation is particularly pertinent if the patient's ambulatory status and underlying medical conditions warrant a conservative approach or if the patient prefers conservative treatment.

---

### Varicose vein surgery after acute isolated superficial vein thrombosis in daily practice: Insights-SVT study [^111pcLHd]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). Low credibility.

In conclusion, this study, based on real-world data, contributes to our understanding of SVT management by highlighting the importance of individualized treatment strategies, appropriate timing of interventions, and the need for continued research to refine our approach to this condition. It reinforces the notion that the management of SVT should be guided by a careful assessment of each patient's individual circumstances and risk factors.

---

### Varicose vein surgery after acute isolated superficial vein thrombosis in daily practice: Insights-SVT study [^113o1NWw]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). Low credibility.

The study flow is illustrated in Fig 1. Of the 872 patients with available 12-month follow-up data, 197 patients (22.6%) underwent invasive treatments at some time point during the follow-up. Among these 197 patients receiving invasive treatments, 70 received such interventions within the first 3 months, 136 patients between 4 and 12 months, and nine patients received invasive treatment twice, spanning both periods.

A total of 817 patients (93.4%) received anticoagulation therapy after the index event as the initial treatment choice at baseline. Of the 197 patients, 182 patients (92.4%) undergoing surgery and 635 of the 675 patients (94.1%) not undergoing surgery received anticoagulation. Furthermore, 141 of 197 patients (71.6%) received some form of non-pharmacological treatment in addition to anticoagulation therapy. The median duration of anticoagulation therapy was 28 days (interquartile range [IQR], 18–42 days) for patients who underwent surgery and 35 days (IQR, 21–42 days) for those who did not.

---

### Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism [^1111TYHe]. The Cochrane Database of Systematic Reviews (2023). High credibility.

Pulmonary embolism (PE) is a potentially life-threatening condition in which a clot can migrate from the deep veins, most commonly in the leg, to the lungs. Conventional treatment of PE used unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, and vitamin K antagonists (VKAs). Recently, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTIs) and oral factor Xa inhibitors. DOACs have characteristics that may be favorable to conventional treatment, including oral administration, a predictable effect, no need for frequent monitoring or re-dosing, and few known drug interactions. This review reports the efficacy and safety of these drugs in the long-term treatment of PE (minimum duration of three months). This is an update of a Cochrane Review first published in 2015.

- **Objectives**: To assess the efficacy and safety of oral DTIs and oral factor Xa inhibitors versus conventional anticoagulants for the long-term treatment of PE.

- **Search methods**: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases, the World Health Organization International Clinical Trials Registry Platform, and the ClinicalTrials.gov trials registers up to 2 March 2022. We checked the reference lists of relevant articles for additional studies.

---

### Editor's choice - European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^111MJnrG]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for varicose veins, specifically with respect to the management of telangiectasias and reticular veins, the ESVS 2022 guidelines recommend obtaining a duplex ultrasound of the lower extremity veins. This is to identify any associated incompetent veins in patients presenting with reticular veins and/or telangiectasias.

---

### Editor's choice - European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^1152KD97]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for varicose veins, more specifically with respect to the management of telangiectasias and reticular veins, the ESVS 2022 guidelines recommend considering offering sclerotherapy or transcutaneous laser therapy in patients with telangiectasias where treatment is planned.

---

### The 2023 society for vascular surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^1177KBWv]. Journal of Vascular Surgery, Venous and Lymphatic Disorders (2024). High credibility.

Evidence

Despite the very low incidence of thromboembolic events among patients undergoing endovenous ablation, one large systematic review did find a significantly lower incidence of EHIT among those receiving pharmacological prophylaxis (1.63% vs. 3.04%; P < .001). However, this was not a uniform finding across individual studies, and there was heterogeneity in the prophylactic regimens used.

Another systematic review included 8 studies (3 RCTs, 5 cohort studies, 6479 patients) comparing pharmacoprophylaxis to no prophylaxis following a variety of varicose vein procedures. Five studies evaluated prophylaxis after open surgery and three after EVLA. The risk of DVT was lower for endovenous procedures than for open surgery. Prophylaxis was associated with a non-significant reduction in the composite risk of DVT, PE, and superficial venous thrombosis (pooled RR, 0.63; 95% CI, 0.04–10.43; p = 0.74) and of DVT alone (pooled RR, 0.59; 95% CI, 0.08–4.60; p = 0.61). There was significant heterogeneity in both results. Notably, confining the analysis to randomized trials did show a significant reduction in the risk of DVT (0.22% vs. 4.15%; RR, 0.05; 95% CI, 0.02–0.13; P < .001).

Among the two studies reporting bleeding risk, there was no difference among those receiving or not receiving prophylaxis. Although a few included studies evaluated the efficacy of fondaparinux and rivaroxaban as well as short vs. extended courses of prophylaxis, conclusions based on the available data are difficult.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^116RTxiv]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Regarding follow-up and surveillance for varicose veins, particularly concerning the management of endothermal heat-induced thrombosis, the AVF/AVLS/SVS 2024 guidelines recommend administering anticoagulation with DOACs over VKAs in patients with asymptomatic ablation-related thrombus extension class III and IV after endovenous ablation.

---

### Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study [^117MmLEP]. The Lancet Haematology (2016). Low credibility.

The efficacy and safety of the anticoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism have been demonstrated in phase 3 trials. However, data about rivaroxaban use in routine clinical practice are needed.

- **Methods**: XA inhibition with rivaroxaban for long-term and initial anticoagulation in venous thromboembolism (XALIA) was a multicenter, international, prospective, non-interventional study of patients with deep-vein thrombosis, conducted in hospitals and community care centers across 21 countries. The study investigated the safety and effectiveness of rivaroxaban compared with standard anticoagulation therapy (initial treatment with unfractionated heparin, low-molecular-weight heparin, or fondaparinux, usually overlapping with and followed by a vitamin K antagonist) for at least 3 months. Eligible patients were adults (aged ≥ 18 years) with an objectively confirmed diagnosis of deep-vein thrombosis and an indication to receive anticoagulation treatment for at least 3 months. Following the approval of rivaroxaban for the pulmonary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism were also eligible; however, those with isolated pulmonary embolism were not included. The type, dose, and duration of therapy for each patient were at the physician's discretion. The primary effectiveness and safety outcomes were major bleeding, recurrent venous thromboembolism, and all-cause mortality. Propensity score-adjusted analyses were conducted to account for potential imbalances between groups.

---

### Juleber [^112NSEAn]. U.S. Food and Drug Administration (2024). High credibility.

- **Royal College of General Practitioners**: Oral contraceptives, venous thrombosis, and varicose veins. J Royal Coll Gen Pract 1978; 28:393–399.

- **Collaborative Group for the Study of Stroke in Young Women**: Oral contraception and increased risk of cerebral ischemia or thrombosis. N Engl J Med 1973; 288:871–878.

- **Petitti DB, Wingerd J**: Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Lancet 1978; 2:234–236.

- **Inman WH**: Oral contraceptives and fatal subarachnoid hemorrhage. Br Med J 1979; 2(6203):1468–1470.

- **Collaborative Group for the Study of Stroke in Young Women**: Oral contraceptives and stroke in young women: associated risk factors. JAMA 1975; 231:718–722.

- **Inman WH, Vessey MP, Westerholm B, Engelund A**: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; 2:203–209.

- **Meade TW, Greenberg G, Thompson SG**: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 35-mcg estrogen preparations. Br Med J 1980; 280(6224):1157–1161.

---

### Benefit of anticoagulation for the treatment of lower extremity superficial venous thrombosis [^112pSsoR]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2015). Low credibility.

Superficial venous thrombosis (SVT) of the lower extremity is an acute disorder characterized by thrombosis and inflammation of superficial veins. This most commonly affects varicose veins but can also occur in patients with nonvaricose veins who may have an underlying condition, such as a malignant disease or thrombophilia. It is important to be aware that SVT confers a significant risk for the development of the more serious and debilitating condition of deep venous thrombosis and the potentially life-threatening condition of pulmonary embolism. Recognition of SVT, determination of the appropriateness of therapy, and institution of timely therapy are paramount to the prevention of deep venous thrombosis and pulmonary embolism in properly selected patients. The objective of this evidence-based summary was to provide clinically applicable information from the literature and guidelines regarding the best treatment options for SVT. There are no randomized trials that compare the efficacy and outcomes of newer therapies, such as the novel oral anticoagulants and endovenous ablation, with traditional therapies, such as traditional anticoagulant and surgical exclusion, in the treatment of SVT.

---

### Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases [^1112i6th]. Hepatology (2017). High credibility.

Regarding medical management for gastroesophageal varices, specifically with respect to the primary prevention of variceal hemorrhage, AASLD 2017 guidelines recommend initiating nonselective β-blockers (propranolol, nadolol), carvedilol, or performing endoscopic variceal ligation for the prevention of first variceal hemorrhage in patients with medium or large varices.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^114KvTzw]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Regarding preventative measures for varicose veins, specifically concerning the prevention of progression, the AVF/AVLS/SVS 2024 guidelines recommend not performing prophylactic intervention to prevent venous disease progression in asymptomatic patients with C2 disease.

---

### Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions [^115ZQdUH]. Annals of Surgery (2023). High credibility.

The primary objective of this systematic review and meta-analysis was to elucidate the rate of venous thromboembolism (VTE) after endovenous interventions for varicose veins in the presence of pharmacological and mechanical thromboprophylaxis versus mechanical thromboprophylaxis alone.

The VTE rate after endovenous procedures for varicose veins is higher than other day-case procedures and could be reduced with pharmacological thromboprophylaxis.

The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines with a registered protocol (PROSPERO: CRD42021274963). Studies of endovenous intervention for superficial venous incompetence reporting the predefined outcomes with at least 30 patients were eligible. Data were pooled with a fixed effects model.

There were 221 trials included in the review:

- **Randomized trial arms**: 47
- **Prospective cohort studies**: 105
- **Retrospective studies**: 69

In randomized trial arms, the rate of deep venous thrombosis with additional pharmacological thromboprophylaxis was 0.52% (95% CI, 0.23%-1.19%) [9 studies, 1095 patients, 2 events] versus 2.26% (95% CI, 1.81%-2.82%) [38 studies, 6951 patients, 69 events] with mechanical thromboprophylaxis alone.

The rate of pulmonary embolism in randomized trial arms with additional pharmacological thromboprophylaxis was 0.45% (95% CI, 0.09%-2.35%) [5 studies, 460 participants, 1 event] versus 0.23% (95% CI, 0.1%-0.52%) [28 studies, 4834 participants, 3 events] for mechanical measures alone. The rate of EHIT grade III to IV was 0.35% (95% CI…).

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^112cLxtD]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Regarding follow-up and surveillance for varicose veins, specifically in the management of endothermal heat-induced thrombosis, the AVF/AVLS/SVS 2024 guidelines recommend administering anticoagulation with DOACs over VKAs in patients who experience symptomatic ablation-related thrombus extension after endovenous ablation.

---

### Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: Systematic review and network meta-analysis of randomised trials [^116AwGWf]. BMJ (2022). High credibility.

In 25 trials involving 30,230 patients, 235 patients (0.78%) had symptomatic venous thromboembolism; in 61 studies involving 40,588 patients, 100 patients (0.25%) had a symptomatic pulmonary embolism; in 13 studies involving 4,343 patients, 42 patients (0.95%) had symptomatic proximal deep vein thrombosis; and in 38 studies involving 32,338 patients, 173 patients (0.53%) had symptomatic deep vein thrombosis of any extension. The results of the network meta-analysis on symptomatic venous thromboembolism, symptomatic pulmonary embolism, and symptomatic proximal and deep vein thrombosis of any extension, for all comparisons, are shown in Table 1 and tables S3-S5.

The certainty of the evidence was high that all of the active treatments probably reduced symptomatic venous thromboembolism compared with no active treatment. Direct oral anticoagulants were associated with a significant (P = 0.02) reduction in symptomatic venous thromboembolism compared with low-dose LMWH (odds ratio 0.53, 95% confidence interval 0.32 to 0.89), but not compared with high-dose LMWH (0.93, 0.51 to 1.71); the certainty of the evidence was moderate. We found no significant difference between the network options on symptomatic pulmonary embolism; the certainty of the evidence was low to moderate. Direct oral anticoagulants, but not LMWH at low or high doses, were superior to no active treatment on symptomatic proximal deep vein thrombosis and deep vein thrombosis of any extension; the certainty of the evidence was low to high, depending on the comparison.

---

### Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: The multicenter, multinational, randomized, open-label ARIVA trial [^113ghFw9]. Circulation (2025). High credibility.

Deep vein thrombosis is the most common clinical manifestation of venous thromboembolism, affecting approximately 2 per 1000 individuals per year. It causes significant morbidity during its acute phase and leads to functional complications months after the initial diagnosis.

Post-thrombotic syndrome (PTS) is the most frequent long-term complication of proximal deep vein thrombosis, occurring in up to 50% of patients with iliofemoral deep vein thrombosis treated with standard anticoagulation and compression stockings. PTS contributes to a substantial individual burden, resulting in long-term morbidity, persistent discomfort, and impaired quality of life for affected patients, often reducing their ability to perform daily activities.

Compression stockings, exercise and physical therapy, wound care, and long-term anticoagulant treatment may relieve the symptoms related to PTS and stabilize the disease. However, no medical treatment has been proven effective to reverse PTS, leading to regression of subjective limitations and symptoms. Recanalization of chronically occluded iliac veins with stent placement has shown, in a randomized trial and multiple single-arm studies, to restore blood flow and alleviate functional limitations associated with PTS.

Several aspects of venous stent placement require further investigation, including the optimal antithrombotic strategy. Currently, there is no agreement on the optimal antithrombotic strategy to prevent venous stent thrombosis, as existing guidelines and consensus documents do not provide definitive recommendations.

---

### EASL clinical practice guidelines for the management of patients with decompensated cirrhosis [^113iPPqj]. Journal of Hepatology (2018). High credibility.

Regarding medical management for variceal hemorrhage, specifically with respect to vasoactive agents, EASL 2018 guidelines recommend administering vasoactive drugs as soon as acute variceal bleeding is suspected and before endoscopy. Administer terlipressin, somatostatin, or octreotide as accepted options. Continue therapy for 3–5 days in patients with acute variceal bleeding.

---

### Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions [^11657xdN]. Annals of Surgery (2023). High credibility.

In total, 221 trial arms and studies were included in the quantitative meta-analysis, involving 476,266 participants (see Figure, Supplemental Digital Content 2, Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagram of included studies). The studies comprised 47 randomized trials, 105 prospective cohort studies, 67 retrospective cohort studies, and 2 case-control studies (Table, Supplemental Digital Content 3, provides a further summary of baseline study data).

The indication for endovenous treatment in all studies was superficial venous incompetence, most commonly defined as > 0.5 seconds in the standing position. This covered a range of clinical, etiological, anatomical, and pathological classification classes from 1 to 6 chronic venous insufficiency. Studies utilized a mixture of endovenous techniques, including endovenous laser ablation, radiofrequency ablation, mechanochemical ablation, cyanoacrylate glue, and ultrasound-guided foam sclerotherapy. The majority examined the great saphenous vein in isolation, though treatments for reflux in the small saphenous vein (SSV) and anterior accessory saphenous vein were also included. The adjunctive use of mini-phlebectomies, avulsions, and/or sclerotherapy for the management of tributaries or perforators was widespread; therefore, data on these were not collected. Most studies excluded participants with a past history of VTE.

There were 43 study arms (13,839 participants) in which mechanical and additional pharmacological thromboprophylaxis were administered, compared to 184 study arms (462,397 participants) where it was not.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^111UgF1V]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Regarding the medical management of varicose veins, specifically in the context of managing bleeding varicose veins, the AVF/AVLS/SVS 2024 guidelines recommend attempting leg elevation, direct compression, and sclerotherapy before resorting to suture ligation to control bleeding in patients presenting with acute bleeding from varicose veins. Promptly refer patients with bleeding from varicose veins to a venous specialist.

---

### Can phlebectomy be deferred in the treatment of varicose veins [^112hpa8G]. Journal of Vascular Surgery (2005). Low credibility.

This study was designed to observe the clinical sequelae of varicose veins after great saphenous vein (GSV) ablation and to assess the possible predictability of spontaneous varicose vein regression.

- **Methods**: Patients with symptomatic varicose veins secondary to GSV insufficiency treated with radiofrequency ablation (RFA) were enrolled. The largest varicose veins in each limb, up to five per patient, were mapped, sized, and documented before RFA. No varicose vein was treated at the time of RFA or within 6 months postoperatively, and their status was recorded at follow-up visits.

- **Results**: Fifty-four limbs in 45 patients were studied, with 222 varicose veins documented before RFA (4.1 ± 1.1 varicose veins per limb), averaging 11.4 ± 3.7 mm in size. During follow-up, complete resolution of visible varicose veins occurred in 13% of limbs with RFA alone, and 28.4% of varicose veins spontaneously resolved. A further 88.7% of varicose veins reduced in size by an average of 34.6% (4.3 ± 3.4 mm). Preoperatively, 19.4% of veins were above and 75.7% below the knee. Complete resolution rates were 41.9% above the knee and 25.6% below. Of the above-knee veins, 88.4% were medial, and 47.4% of resolved ones were medial. Below-knee varicose vein resolution rates were 30.6% for medial, 23.1% for anterior, 20.0% for lateral, and 5.3% for posterior veins.

- **Conclusions**: Great saphenous vein ablation leads to a significant reduction in varicose veins, but further research is needed to optimize treatment strategies.

---

### Selection of saphenous vein conduit in varicose vein disease [^1166Zfgp]. The Annals of Thoracic Surgery (2006). Low credibility.

Limbs with varicose veins are difficult to assess as a source of saphenous vein conduit. Anatomic, histologic, and ultrasound studies demonstrate two types of longitudinal veins in the lower extremities. The great saphenous vein is deep to the saphenous fascia. Accessory saphenous veins are superficial to this layer and have thin walls with diminished muscle cells and elastic fibers. Accessory saphenous veins dilate and form varicosities. Segments of great saphenous veins are often suitable as coronary conduits. No studies have assessed the suitability of saphenous veins as coronary artery conduits in patients with varicose vein disease.

- **Methods**: Intraoperative high-resolution ultrasound studies were performed in coronary artery bypass graft procedures to assess lower extremity venous morphology in limbs of 77 patients without known venous disease, in 19 limbs with venous telangiectases, and in 23 limbs with varicose veins.

- **Results**: Dilated great saphenous vein segments were identified in 6% of normal limb venous segments compared with 21% of segments in limbs with telangiectases (p = 0.027) and 22% of segments in limbs with varicosities (p = 0.012). The incidence of absent or hypoplastic great saphenous vein segments is increased in limbs with varicosities (35%) compared with normal limbs (21%; p = 0.032). In the calf, at least one great saphenous vein segment suitable for coronary artery bypass grafting is present in 70% of limbs with varicosities and in 89% of limbs with telangiectases.

- **Conclusions**: Ultrasound studies document that varicose veins are limited in their use for coronary artery bypass due to the reduced availability of appropriate saphenous vein segments.

---

### Management of uncomplicated varicose veins - a case vignette for a clinical decision proposal [^117XsPsb]. European Journal of Vascular and Endovascular Surgery (2012). Low credibility.

Venous disorder is common in the general population. Uncomplicated varicose veins represent a significant proportion of the disease burden and can considerably impact quality of life by producing a wide spectrum of symptoms. Little is known about the natural course of the disease at this stage, and the treatment strategy employed is often not based on robust scientific evidence. The aim of this article is to elucidate the options to manage uncomplicated varicose veins.

There are likely to be significant geographic differences in the treatment strategy employed. It is hoped that we will provoke discussion among physicians regarding the management of this very common medical condition. The reader will be asked for their preferred treatment choice for a given clinical case vignette.

---

### Oral rivaroxaban for symptomatic venous thromboembolism [^117CffWw]. The New England Journal of Medicine (2010). High credibility.

Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.

- **Methods**: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study.

- **Results**: The study of rivaroxaban for acute DVT included 3,449 patients: 1,731 given rivaroxaban and 1,718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%] vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval, 0.44 to 1.04; P < 0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients, additional results would be needed to complete the analysis.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^117BbyhV]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

The recurrence rate of superficial vein thrombosis (SVT) is between 10% and 20%. A large case series of SVT patients described a recurrence rate of 15% among 221 patients. With the widespread application of anticoagulant therapies, the risk of recurrence or venous thromboembolism (VTE) is approximately 6%, with the highest risk occurring among patients with previous episodes of SVT and long segment thrombosis. Although not addressed by a randomized control trial, best practice includes informing patients of the risk of recurrent SVT and offering surgical or endovascular therapy for the treatment of symptomatic recanalized varices and axial reflux, if present in the recanalized saphenous vein after completion of evidence-based antithrombotic therapy.

- **Management of bleeding varicose veins**:
	- For patients presenting with acute bleeding from varicose veins, leg elevation, direct compression, and sclerotherapy should be attempted before suture ligation is used to control bleeding.

	- For patients with bleeding due to varicose veins, a prompt referral to a venous specialist should be made.

	- For patients who present with bleeding from varicose veins, and their bleeding has been controlled, evaluation for superficial venous incompetence and appropriate intervention should be performed to control venous hypertension and reduce the risk of re-hemorrhage.

	- Patients with varicose veins or venous ulcerations should be counseled on the possibility of venous bleeding, and their families, caregivers, or friends should be educated regarding leg elevation and simple compression.

---

### Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis [^117Cc4ub]. Blood Advances (2022). Low credibility.

Oral anticoagulants are commonly used for the treatment of patients with a confirmed diagnosis of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), and for stroke prevention among patients with atrial fibrillation who are at high risk of stroke. For several decades, vitamin K antagonists (VKAs), primarily warfarin, were the only available oral anticoagulants, resulting in significant experience with their use. However, VKA use has drawbacks, including a narrow therapeutic window that warrants frequent monitoring of the international normalized ratio, drug interactions with numerous medications, and food interactions with vitamin K-rich food.

Meanwhile, direct oral anticoagulants (DOACs) were developed to overcome these limitations. DOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban, are oral anticoagulants approved for use in the prevention and treatment of thrombosis in several cardiovascular indications. VTE among patients with SCD is associated with a 2 to 4 times increase in mortality risk compared with patients with SCD without VTE. Nevertheless, the evidence guiding the management of VTE in SCD, specifically in terms of the anticoagulant of choice, is scarce.

Therefore, we conducted a systematic review and meta-analysis to address this important question. The aim of this systematic review and meta-analysis was to evaluate DOAC effectiveness and safety in SCD.

---

### A review of the current management and treatment options for superficial venous insufficiency [^115grmAQ]. World Journal of Surgery (2014). Low credibility.

The recognition of lower extremity venous disease as a significant cause of morbidity and reduced quality of life, affecting up to 25% of Western populations, has prompted rapid and drastic improvements in treatment options and increased awareness of the disease. Superficial venous disease, a frequent medical problem encountered in clinical practice, is now a common reason for referrals to providers offering a spectrum of interventions.

Venous guidelines have been established by the American Venous Forum and Society for Vascular Surgery, covering conditions from simple spider veins to chronic venous ulcerations. This review provides an overview of the modern management of varicose veins and venous insufficiency.

---

### Treatment of varicose veins affects the incidences of venous thromboembolism and peripheral artery disease [^115zbpYv]. Circulation: Cardiovascular Interventions (2021). Low credibility.

Analysis of recent clinical data reveals significant correlations between the treatment of varicose veins and the incidences of venous thromboembolism (VTE) and peripheral artery disease (PAD). Understanding these correlations is crucial for healthcare professionals when considering treatment options for patients with varicose veins. The study highlights the importance of monitoring patients for VTE and PAD following treatment to minimize potential health risks.

By employing rigorous methodologies, the research aims to clarify the relationship between varicose vein treatments and the development of these conditions. The findings suggest that further exploration into patient management strategies could enhance clinical outcomes.

---

### Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases [^1152wViT]. Hepatology (2017). High credibility.

Regarding preventative measures for variceal hemorrhage, particularly in primary prevention, the AASLD 2017 guidelines recommend initiating traditional nonselective β-blockers (such as propranolol and nadolol), carvedilol, or performing endoscopic variceal ligation. These measures are advised for the prevention of the first variceal hemorrhage in patients with medium or large varices.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^116Hg5cC]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Regarding medical management for varicose veins, particularly in relation to phlebotonics, the 2024 guidelines from AVF/AVLS/SVS recommend considering the use of micronized purified flavonoid fraction or *Ruscus aculeatus* extract. These treatments are suggested for addressing vein-related pain, leg heaviness, and/or a sensation of swelling in symptomatic patients who are ineligible for intervention, awaiting intervention, or experiencing symptoms following an intervention.

---

### The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex scanning and treatment of superficial truncal reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology [^112RtMA6]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2023). High credibility.

Regarding therapeutic procedures for varicose veins, specifically concerning the management of incompetent perforating veins, the AVF/AVLS/SVS 2023 guidelines recommend avoiding treatment of incompetent perforating veins in conjunction with the initial ablation of the superficial truncal veins in patients with varicose veins (CEAP class C2) who have significant, symptomatic axial reflux of the anterior or posterior accessory great saphenous vein.

---

### A different way to look at varicose veins [^114yDCDk]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2014). Low credibility.

The development of varicose veins is commonly attributed to vessel wall degeneration. However, the idea that varicose veins occur solely due to pathological processes is challenged by certain observations. For instance, their high prevalence (50% or greater) in many populations classifies them as statistically "normal". This prevalence, coupled with a well-established genetic predisposition, raises the possibility that varicose veins confer a survival benefit. It is theorized that varicose veins are produced by the same mechanisms responsible for the growth and remodeling of other blood vessels. Being "good" at forming varicose veins may predispose individuals to efficiently form various types of collateral blood vessels when necessary.

A selected literature review was conducted, focusing on works suggesting that the formation of varicose veins may share basic mechanisms with the formation of collateral veins, arteries, and lymphatic vessels. Additionally, clinical outcomes were compared between subjects with and without varicose veins.

Evidence suggests that individuals proficient in forming varicose veins may also excel in forming various types of collateral vessels, potentially leading to better overall survival with less cardiovascular morbidity compared to those without varicose veins.

In conclusion, varicose veins may represent "the price we pay" for an enhanced ability to form collateral vessels when necessary.

---

### Editor's choice - European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs [^117DfUJU]. European Journal of Vascular and Endovascular Surgery (2022). High credibility.

Regarding therapeutic procedures for varicose veins, specifically concerning the management of telangiectasias and reticular veins, the ESVS 2022 guidelines recommend treating significant associated incompetent veins first before considering treatment for smaller veins in patients presenting with reticular veins and/or telangiectasias.

---

### Historical overview of varicose vein surgery [^112Zrpgi]. Annals of Vascular Surgery (2010). Low credibility.

Varicose veins have been recognized since the time of Hippocrates. Various treatments for varicose veins have come and gone. Surgery for varicose vein disease is among the most common elective general surgical procedures. The history of varicose vein surgery includes the earliest descriptions of these veins.

- **Surgical techniques**: The focus includes ligation of the saphenofemoral junction, stripping of the great saphenous veins, phlebectomy, and perforant vein surgery.

- **Minimally invasive procedures**: The rapid rise of minimally invasive procedures such as foam sclerotherapy, radiofrequency ablation, and endovenous laser therapy has been significant. Within the past decade, the advantages of minimal invasiveness for these procedures, combined with claims of equivalent short-term outcomes and potentially better long-term results, have influenced everyday practice.

At present, the gold standard treatment of varicose veins remains surgical ligation and stripping of the insufficient vein. Concomitant or sequential treatment of truncal insufficiency with phlebectomy addresses residual varicosities. However, new minimally invasive techniques have dramatically transformed the clinical landscape of varicose vein surgery. The dramatic changes of the past decade likely foreshadow the innovations of the next generation.

---

### Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions [^115AmgiR]. Annals of Surgery (2023). High credibility.

The rate of deep vein thrombosis (DVT) was extracted from all 221 studies. For randomized trial arms, the rate of DVT in the mechanical and additional pharmacological thromboprophylaxis arms was 0.52% [95% confidence interval (CI) 0.23%–1.19%] (9 trial arms, 1095 patients, 2 events) (Fig. 1). For mechanical thromboprophylaxis alone, the rate of DVT was 2.26% (95% CI, 1.81%–2.82%) (38 trial arms, 6951 patients, 69 events) (Fig. 2). Heterogeneity, expressed via I², was 0% and 62%, respectively.

Across all prospective study designs, the rate of DVT in the additional pharmacological thromboprophylaxis arms was 0.73% (95% CI, 0.52%–1.02%) (31 study arms, 6151 participants, 23 events, I² = 0%) versus 1.31% (95% CI, 1.16%–1.48%) (123 study arms, 36,418 participants, 214 events, I² = 60%) for mechanical thromboprophylaxis alone. For the combined study arms (encompassing all retrospective and prospective study designs), the DVT rate for the additional pharmacological thromboprophylaxis arms was 0.71% (95% CI, 0.57%–0.89%) (43 trial arms, 13,869 participants, 63 events, I² = 0%).

For mechanical thromboprophylaxis alone, the heterogeneity of 93% precluded quantitative synthesis and prompted further enquiry into between-study differences.

---

### Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: The multicenter, multinational, randomized, open-label ARIVA trial [^111iR627]. Circulation (2025). High credibility.

In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first six months after intervention. The ARIVA trial (Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS) tested whether 100 mg of daily aspirin plus 20 mg of rivaroxaban is superior to 20 mg of rivaroxaban alone to prevent stent thrombosis within six months after stent placement for post-thrombotic syndrome.

- **Methods**: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score greater than four points and a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein successfully treated with venous stent placement were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included 75 years of age, contraindications to anticoagulant use, or acute venous thrombosis less than three months. The primary efficacy outcome was the composite of no occlusion in the treated segment assessed at serial duplex ultrasound examinations or no reintervention needed to maintain patency within six months. Secondary outcomes, including Villalta score, quality of life, and safety outcomes, were also assessed. The study was registered at ClinicalTrials.gov (NCT04128956).

- **Results**: From 2020 through 2022, 172 patients were screened, 169 were randomized, and 162 were included in the full analysis set.

---

### Temporal trends in the practice pattern for venous thromboembolism in Japan: Insight from JROAD-DPC [^115DGTnz]. Journal of the American Heart Association (2020). Low credibility.

Recently, direct oral anticoagulants have been introduced for venous thromboembolism, which might change the management strategies of venous thromboembolism. However, there have been limited data on the real-world practice pattern in Asian countries.

- **Methods and results**: The JROAD-DPC (Japanese Registry of All Cardiac and Vascular Diseases–Diagnosis Procedure Combination) is a nationwide claim database from 1,022 hospitals in Japan between April 2012 and March 2017. We identified 54,369 patients who were hospitalized with a diagnosis of venous thromboembolism at admission based on the International Classification of Diseases, Tenth Revision (ICD-10) code. The mean age was 69.1 ± 15.6 years, 59% were women, and the mean body mass index was 23.5 ± 5.0 kg/m².

	- The proportion of patients with deep vein thrombosis decreased over time from 72% in 2012 to 38% in 2017. After the release of direct oral anticoagulants, the proportion of patients receiving direct oral anticoagulants increased dramatically among patients with anticoagulation therapy at discharge, with the use of edoxaban, rivaroxaban, and apixaban in 35%, 22%, and 27% of patients, respectively, in 2017. On the other hand, the proportion of patients receiving warfarin decreased from 94% in 2012 to 15% in 2017.

	- The median length of a hospital stay decreased over time from 20 days in 2012 to 13 days in 2017 in patients with pulmonary embolism, and from 14 days in 2012 to 12 days in 2017 in patients with deep vein thrombosis. The median cost of hospitalization for pulmonary embolism moderately decreased over time, whereas that for deep vein thrombosis was not specified.

---

### Varicose vein surgery after acute isolated superficial vein thrombosis in daily practice: INSIGHTS-SVT study [^113bbQt2]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). Low credibility.

Lines represent cumulative event rates in percent, along with their 95% confidence intervals (CIs) over time until 12 months, categorized by type of intervention. EVTA refers to endovenous thermal ablation, and SFJ/SPJ refers to the ligation of the saphenofemoral or saphenopopliteal junction.

A great majority of patients enrolled in the registry (93.4%) received anticoagulation at baseline. Notably, concerning both anticoagulant and non-pharmacological treatments, the differences between patients who underwent surgery and those who did not were minimal and did not reach statistical significance. Specifically, among patients who received surgery compared with those who did not, fondaparinux was administered at baseline to 125 patients (63.5%) versus 417 (61.8%); low molecular weight heparins were given to 48 patients (24.4%) versus 170 (25.2%), and other anticoagulants (direct oral anticoagulants, vitamin K anticoagulants, and unfractionated heparin) were used by nine patients (4.6%) versus 48 (6.7%). Additionally, non-pharmacological treatment was utilized by 141 patients (71.6%) who underwent surgery.

The primary outcome of symptomatic VTE within the initial 3 months of follow-up was observed in 51 patients (7.6%) treated conservatively, which included 37 patients with varicose veins and 14 patients without varicose veins. In contrast, 16 patients (8.1%) who underwent surgical treatment experienced this outcome. Importantly, this data indicates that there was no significant difference between the two groups in terms of symptomatic VTE within the first 3 months.

---

### Direct oral anticoagulants for the treatment of splanchnic vein thrombosis - a systematic review and meta-analysis [^1135Sgku]. Thrombosis Research (2023). Low credibility.

Splanchnic vein thrombosis (SVT) is an uncommon manifestation of venous thromboembolism in the splanchnic venous system, with scarce evidence surrounding its management. We assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to low-molecular-weight heparins (LMWH), vitamin-K antagonists (VKAs), or no anticoagulation.

- **Methods**: We conducted a systematic review and meta-analysis with the primary efficacy outcome being complete recanalization of affected vessels and the primary safety outcome being major bleeding. The meta-analysis was done using a random-effects model, with dichotomous outcomes being synthesized with odds ratios (ORs) and corresponding 95% CIs.

- **Results**: Seven non-randomized and one randomized study involving 883 participants were included for analysis. DOACs were more effective than VKAs (OR = 4.33; 95% CI: 2.4, 7.83; n = 1 study) in non-cirrhotic patients and no anticoagulation in cirrhotic patients (OR = 3.86; 95% CI: 1.49, 10.03; n = 3 studies). DOACs showed a statistically significant reduction in major bleeding compared to observation (OR = 0.09; 95% CI: 0.03, 0.29; n = 3 studies), LMWHs (OR = 0.13; 95% CI: 0.03, 0.29; n = 1 study) and VKAs (OR = 0.12; 95% CI: 0.02, 0.69; n = 2 studies) in non-cirrhotic patients. No difference in major bleeding was found between DOACs and observation, LMWH, or VKAs in cirrhotic patients.

- **Conclusion**: DOACs appear to be a favorable alternative to VKAs and LMWHs in non-cirrhotic patients. This avenue of research would benefit from larger studies that adjust for SVT etiologies and patient risk factors.

---

### Sodium tetradecyl sulfate [^111FRP98]. U.S. Food and Drug Administration (2024). High credibility.

Sotradecol (sodium tetradecyl sulfate injection) is indicated for the treatment of small, uncomplicated varicose veins of the lower extremities that exhibit simple dilation with competent valves. The benefit-to-risk ratio should be carefully considered in selected patients who are at high surgical risk.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^1174x9Hp]. Journal of Vascular Surgery. Venous and Lymphatic Disorders (2024). High credibility.

- **Management of SVT in patients with varicose and nonvaricose veins**: The guideline addresses the management of SVT in patients who have not recently undergone superficial venous interventions. The management of EHIT and other thrombotic complications of superficial venous interventions were presented in Guidelines 11.

	- **12.1.1**: For patients with SVT of the main saphenous trunks and tributaries above the knee > 3 cm from the SFJ and ≥ 5 cm in length, whether or not associated with varicose veins, fondaparinux 2.5 mg subcutaneously daily for 45 days is recommended; alternatively, rivaroxaban 10 mg/d for 45 days may be appropriate for patients unwilling or unable to perform subcutaneous injections. Grade of recommendation: 1 (strong), Quality of Evidence: A (high).

	- **12.1.2**: For patients with SVT of the main saphenous trunks ≤ 3 cm from the SFJ, treatment with full anticoagulation for a minimum of 6 weeks should be continued.

	- **12.1.3**: For patients with SVT of the main saphenous trunks, it is suggested to avoid using prophylactic or therapeutic dose low-molecular weight heparin (LMWH) and nonsteroidal anti-inflammatory drugs (NSAIDs). While both have been found to reduce SVT pain and extension, they have failed to prevent VTE. If NSAIDs are used for treatment of short segment distal SVT, surveillance with DUS for VTE extension is recommended due to the high prevalence of concomitant DVT. Grade of recommendation: 1 (strong), Quality of Evidence: A (high).

	- **12.1.4**: For selected patients with isolated thrombosis of varicose tributaries or limited involvement [text is incomplete, additional context required].

---

### Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism [^111Lw6Cb]. The Cochrane Database of Systematic Reviews (2017). Low credibility.

Currently, little evidence is available on the length and type of anticoagulation used for extended treatment for the prevention of recurrent venous thromboembolism (VTE) in patients with unprovoked VTE who have completed initial oral anticoagulation therapy.

- **Objectives**: To compare the efficacy and safety of available oral therapeutic options (aspirin, warfarin, direct oral anticoagulants (DOACs)) for extended thromboprophylaxis in adults with a first unprovoked VTE, aiming to prevent VTE recurrence after completing an acceptable initial oral anticoagulant treatment period as defined in individual studies.

- **Search methods**: For this review, the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (March 2017) as well as the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2). Trials registries (March 2017) and reference lists of relevant articles were also searched.

- **Selection criteria**: We included randomized controlled trials in which patients with a first, symptomatic, objectively confirmed, unprovoked VTE, who had been initially treated with anticoagulants, were randomized to extended prophylaxis (vitamin K antagonists (VKAs), antiplatelet agents, or DOACs) versus no prophylaxis or placebo. Trials comparing one type of extended prophylaxis versus another type of extended prophylaxis were also included.

- **Data collection and analysis**: Two review authors independently selected studies, assessed quality, and extracted data. Disagreements were resolved by discussion.

- **Main results**: Six studies with a combined total of 3436 patients were included.

---

### The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine [^116AbJhA]. Journal of Vascular Surgery: Venous and Lymphatic Disorders (2024). High credibility.

Evidence

Nonsaphenous, pelvic origin varicose veins occur in women in the medial and posterior thigh, vulva, and inguinal area. They result from reflux from the internal iliac vein through the inguinal, obturator, perineal, and gluteal escape points. Vulvar varicosities are estimated to occur in 22% to 34% of women with varicose veins of the pelvis and in 18% to 22% of pregnant women.

Seventy-two symptomatic patients with pelvic source varicose veins were studied; however, only 7% had chronic pelvic pain. In a systematic review of 13 studies on ovarian vein embolization in 866 women, technical success was 99.8% with significant improvement in pelvic pain reported in nine studies. In one study, lower extremity varicosities recurred only in 13% at five years after embolization. Hartung et al. reported 51% improvement in lower extremity varicosity following ovarian vein embolization in 119 women who had both pelvic symptoms and lower extremity varicose veins. In another study of 43 patients, Castenmiller et al. showed improvement after ovarian vein embolization in the lower extremity varicose veins in 14%, but the success rate was 88% for treatment of vulvar varicose veins.

Gavrilov reported good clinical results with direct treatment of vulvar varicosities with FS and phlebectomy. In 32 patients with asymptomatic pelvic varicose veins, phlebectomy alone for vulvar varices resulted in no recurrence at 3 to 8 years after the procedure. Sclerotherapy was effective at 1 year in 10 of 12 patients. The consensus of experts supports the strategy of direct treatment of pelvic origin varicose veins.

---

### Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis [^112xokAm]. The Cochrane Database of Systematic Reviews (2023). High credibility.

Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly in the leg, occurring in approximately one in 1000 people. If left untreated, the clot can travel to the lungs and cause a potentially life-threatening pulmonary embolism (PE). Previously, DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTIs) and oral factor Xa inhibitors. These have characteristics that may be favorable compared to conventional treatment, including oral administration, a predictable effect, lack of frequent monitoring or dose adjustment, and few known drug interactions. DOACs are now commonly used for treating DVT; recent guidelines recommend DOACs over conventional anticoagulants for both DVT and PE treatment.

This Cochrane Review was first published in 2015 and was the first systematic review to measure the effectiveness and safety of these drugs in the treatment of DVT. This is an update of the 2015 review, aiming to assess the effectiveness and safety of oral DTIs and oral factor Xa inhibitors versus conventional anticoagulants for the long-term treatment of DVT.

- **Search methods**: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases, as well as the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers, up to 1 March 2022.

---

### Risk indicators for varicose veins in forty- to sixty-year-olds in the Tampere varicose vein study [^115HBdjL]. World Journal of Surgery (2002). Low credibility.

The objectives of the study were to discover the main determinants for the prevalence of varicose veins in a general population, and to assess the possibilities for prevention of this common surgical disease. Varicose veins were evaluated in three defined cohorts of 3,284 men and 3,590 women aged 40, 50, and 60 years by using a validated questionnaire. The response rate was 75% among men and 86% among women, and varicose veins were determined by self-assessment.

Increasing age, female sex, childbirths, standing posture at work, higher weight or height, and positive family history were significantly associated with varicose veins in a univariate analysis. These factors were further analyzed using a multivariate logistic regression analysis, revealing significant risk indicators:

- **Female gender**: Adjusted odds ratio (OR) of 2.2
- **Increasing age**: OR of 2.2–2.8
- **Positive family history for varicose veins**: OR of 4.9
- **Increasing number of births**: OR of 1.2–2.8
- **Standing posture at work**: OR of 1.6
- **Higher weight**: OR of 1.2
- **Higher height**: OR of 1.4

Increasing age, a positive family history of varicose veins, and childbirth in women were the most important factors in terms of population etiologic fractions. Familial predisposition and pregnancy-related factors show important associations with varicose veins. Thus, prevention of varicose veins appears to be difficult. Varicose veins are nonlethal, and therefore, higher age is related to higher prevalence.